Summary
This article presents data indicating that treatment with an all-oral fixed-dose combination of daclatasvir/asunaprevir/beclabuvir with or without the addition of ribavirin is associated with high rates of sustained viral response to treatment 12 weeks after therapy in patients with chronic compensated cirrhosis and hepatitis C virus genotype 1 infection.
- Liver Conditions Hepatology Clinical Trials
- Viral Infections
- Liver Conditions
- Hepatology
- Hepatology Clinical Trials
- Viral Infections
- © 2014 MD Conference Express®
Tools
DCV/ASV/BCV Improves Sustained Viral Response in Patients with Chronic HCV GT-1 Infection and Compensated Cirrhosis: UNITY-2 Results
Permalink:
Table of contents
Cited By...
- No citing articles found.